Journal article icon

Journal article

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Abstract:

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with certolizumab pegol that was first published in 2011. OBJECTIVES: To assess the clinical benefits and harms of certolizumab pegol (CDP870) in patients with RA who have not responded well to conventi...

Expand abstract

Actions


Access Document


Publisher copy:
10.1002/14651858.cd007649.pub3

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Primary Care Health Sciences
Role:
Author


Journal:
Cochrane database of systematic reviews More from this journal
Volume:
9
Pages:
CD007649
Publication date:
2014-01-01
DOI:
EISSN:
1469-493X


Language:
English
Pubs id:
pubs:139031
UUID:
uuid:bebb29b0-bc5c-473b-94c9-b01c587d84be
Local pid:
pubs:139031
Source identifiers:
139031
Deposit date:
2012-12-19

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP